Retatrutide
LY3437943 · Reta · Triple-G
Last updated
At a glance
Overview
Why Retatrutide Is the Most Talked-About Fat Loss Compound of the Decade#
Retatrutide is the first triple agonist to hit the grey market — a single peptide that activates the GLP-1, GIP, and glucagon receptors in one shot. The first two receptors are the tirzepatide story: appetite suppression, slower gastric emptying, better glucose handling. The glucagon arm is what makes retatrutide different. It raises energy expenditure and drives hepatic fat oxidation, so you're not just eating less — energy expenditure is increased. That's why phase 2 data landed harder than anything had been observed from sema or tirz.
"At 48 weeks, the mean percentage change in body weight ranged from −8.7% (1 mg) to −24.2% (12 mg)...weight reduction had not yet reached a plateau in the highest-dose groups." — Jastreboff et al., NEJM 2023
For physique-focused users, the appeal is specific: retatrutide hits visceral fat and liver fat hard (useful after a blast of orals), it works at lower doses than the trial max because most of us aren't trying to lose 80 lb, and the ~6-day half-life (Urva et al., Lancet 2022) makes a clean once-weekly injection schedule that plays well with the rest of a cycle. Stack it with TRT-dose testosterone and heavy lifting and muscle is preserved while the fat peels off faster than any diet alone can deliver.
The rest of this page covers the protocol details: weekly dosing and titration schedules, use-case protocols (aggressive cut, mini-cut, recomp, post-blast cleanup, plateau-breaker for sema/tirz veterans), stacking with testosterone and GH, managing the GI side effects and heart rate bump, bloodwork cadence, and the pitfalls — muscle loss, over-titration, and rebound — that separate users who keep their results from users who don't.
How Retatrutide works
Triple Receptor Agonism — The Core Design#
Retatrutide is a single 39-amino-acid peptide engineered to activate three metabolic receptors simultaneously: the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R). A C20 fatty diacid side chain binds albumin, extending the half-life to ~6 days and enabling once-weekly dosing.
In vitro binding studies show balanced GCGR and GLP-1R activity with relatively stronger GIPR potency — a deliberate design choice that layers three complementary fat-loss mechanisms into one molecule.
"LY3437943 is a novel triple agonist at the glucagon, GIP, and GLP-1 receptors, offering significant glycemic control and robust body weight reduction in both preclinical and clinical studies." — Coskun T. et al., Cell Metabolism, 2022
GLP-1R Agonism — Appetite and Gastric Emptying#
The GLP-1 arm is the familiar semaglutide/liraglutide mechanism. Activation of GLP-1 receptors in the hypothalamus (particularly POMC neurons in the arcuate nucleus) drives central appetite suppression, while peripheral GLP-1R activity slows gastric emptying and enhances glucose-dependent insulin secretion.
Practical outcome: you feel full faster, stay full longer, and eat noticeably less without consciously restricting. This is the arm responsible for most of the first-week appetite drop users feel on low doses.
GIPR Agonism — Adipocyte Handling and Satiety Synergy#
The GIP receptor arm — the same component that differentiates tirzepatide from semaglutide — adds glucose-dependent insulin release and, more importantly for physique users, direct effects on adipocytes that appear to improve lipid handling and buffer against the nausea ceiling of pure GLP-1 agonism. GIPR activity also potentiates the central satiety effect of the GLP-1 arm.
Practical outcome: more fat loss per unit of appetite suppression than a GLP-1 mono-agonist, and typically better GI tolerability at equivalent weight-loss efficacy than semaglutide.
GCGR Agonism — The Thermogenic Differentiator#
This is what separates retatrutide from every other incretin on the market. Glucagon receptor activation in hepatocytes and adipose tissue increases resting energy expenditure, drives hepatic lipolysis and fatty acid oxidation, and mobilizes intrahepatic fat. In plain terms: the GCGR arm makes you burn more, not just eat less.
This is why retatrutide produced the largest weight-loss numbers of any pharmacologic agent tested to date, with no plateau at 48 weeks in the higher-dose arms:
"At 48 weeks, the mean percentage change in body weight ranged from −8.7% (1 mg) to −24.2% (12 mg)...weight reduction had not yet reached a plateau in the highest-dose groups." — Jastreboff A.M. et al., New England Journal of Medicine, 2023
The trade-off: at higher doses, the glucagon arm can modestly raise fasting glucose in non-diabetics. Usually offset by the GLP-1/GIP arms, but worth monitoring if you already run elevated FBG on cycle.
Hepatic Fat Mobilization#
The GCGR component has a distinct downstream effect worth calling out separately: direct reduction of liver fat. This matters for anyone coming off a heavy oral AAS run, an extended bulk, or a period of metabolic neglect — hepatic steatosis is common in all three populations and notoriously sticky.
"Retatrutide treatment resulted in significant reduction of liver fat content and improvement in markers of liver health in patients with metabolic dysfunction-associated steatotic liver disease." — Sanyal A.J. et al., Nature Medicine, 2024
Practical outcome: retatrutide addresses visceral adiposity, hepatic fat, lipid profile, and insulin sensitivity simultaneously — which is why it's become the go-to post-blast metabolic reset for experienced users.
Net Physiological Effect#
Stacking the three arms produces an effect no mono- or dual-agonist can replicate: reduced intake (GLP-1) + improved substrate handling (GIP) + increased expenditure (glucagon). You eat less and burn more, and the hepatic/adipose effects mean the fat that does come off includes the visceral and intrahepatic stores that matter most for long-term metabolic health. The single limiting factor in a physique context is protein intake — appetite suppression at 4+ mg is aggressive enough that hitting protein becomes a discipline problem, not a hunger one.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 0.5–1 mg | Weekly | Documented entry-level range |
| Mid | 2–4 mg | Weekly | Most commonly studied range |
| High | 6–8 mg | Weekly | Once weekly SC is the clinically validated cadence. Some users split into two half-doses per week (e.g. Mon/Thu) to flatten GI side effects — PK-justified by the 6-day half-life. Titrate up by 1mg every 3–4 weeks, not faster. |
Cycle length & outcomes
Documented cycle
12–24 weeks
Plateau after
48 wks
Cycle Length & Structure#
Retatrutide is a titration compound, not a cycle compound in the AAS sense. You don't blast and cruise — you step the dose up gradually over weeks, hold at an effective maintenance dose until goal body composition is reached, then taper down rather than stopping cold. The 6-day half-life means steady state takes ~4–5 weeks at any fixed dose, which dictates the titration cadence.
"The mean terminal half-life of LY3437943 was approximately 6 days, supporting once-weekly dosing in further clinical studies." — Urva et al. 2022, The Lancet
Protocol by Goal#
| Goal | Cycle Length | Weekly Dose | Titration |
|---|---|---|---|
| Mini-cut / post-bulk cleanup | 6–10 weeks | 0.5–2 mg | 0.5 → 1 → 2 mg, 3 weeks each step |
| Recomp (slow burn) | 16–24 weeks | 0.5–1 mg steady | Start 0.5 mg, only move to 1 mg if stalled |
| Aggressive cut | 12–20 weeks | Titrate to 4–6 mg | 1 → 2 → 4 → 6 mg, 4 weeks per step |
| Contest prep / high body fat start | 20–24 weeks | Titrate to 6–8 mg | 2 → 4 → 6 → 8 mg, 4 weeks per step |
| Post-cycle metabolic reset | 12 weeks | 2–4 mg | 1 → 2 → 4 mg, 4 weeks per step |
| Plateau-breaker after sema/tirz | 12–16 weeks | 2–6 mg | Wash out prior GLP-1 2 weeks, then 2 → 4 → 6 mg |
Titration Rules#
Never move up faster than every 3–4 weeks. This is non-negotiable. The phase 2 protocol used 4 weeks per step, and the fast-titration arm (4 → 8 mg) finished with less weight loss than the slow-titration 8 mg arm — likely because aggressive titration produced enough GI symptoms to tank adherence.
"At 48 weeks, the mean percentage change in body weight ranged from −8.7% (1 mg) to −24.2% (12 mg)...weight reduction had not yet reached a plateau in the highest-dose groups." — Jastreboff et al. 2023, NEJM
If nausea, fatigue, or food aversion is still significant at the end of a 4-week step, hold the current dose for another 2–4 weeks before stepping up. The compound keeps working at sub-maximal doses — there's no penalty for titrating slowly.
Onset Timing#
- Week 1–2: appetite suppression noticeable within 48–72 hours of first injection. Early nausea peaks here.
- Week 3–4: first steady state reached at starting dose. Scale weight starts moving consistently.
- Week 6–8: GI side effects typically subside even as dose climbs, assuming slow titration.
- Week 12–16: most dramatic visible recomposition, especially visceral fat and waistline.
- Week 24+: weight loss continues but slows; this is when most community users either step down to a maintenance dose or begin tapering off.
Do not judge the compound in the first 2 weeks. Early nausea without dramatic weight movement is the norm — fat loss compounds steadily and doesn't plateau until 8+ months on trial doses.
Split-Dose Option#
Weekly is the default, but twice-weekly half-dosing is pharmacokinetically sound given the 6-day half-life. Users prone to GI side effects often split (e.g., 1 mg Monday + 1 mg Thursday instead of 2 mg once weekly) to flatten the post-injection peak. No efficacy penalty — steady-state exposure is effectively identical.
Bloodwork Cadence#
- Baseline (week 0): CBC, CMP, lipid panel, HbA1c, fasting insulin, lipase, TSH
- Week 8–12: CMP (liver + kidney), lipase if any GI symptoms, HbA1c and lipids to track efficacy
- Week 20–24: full repeat if running long-duration protocols
- At home: weekly resting heart rate (flag a persistent +15 bpm), weekly morning weight, protein intake log
Lipase bump without abdominal pain is a class finding and usually not actionable. Lipase bump with persistent upper-abdominal pain = stop and get imaged.
Tapering Off#
Unlike AAS, retatrutide doesn't require PCT — there's no HPTA involvement. But do not stop cold from a high dose. Rebound hunger and weight regain are real and well-documented across the GLP-1 class.
Taper protocol: step the dose down by 1–2 mg every 3–4 weeks until you reach 0.5–1 mg/week, then hold that maintenance dose for 8–12 weeks while you rebuild eating habits at your new body weight. Many users run a permanent micro-dose (0.25–0.5 mg/week) as long-term maintenance rather than discontinuing entirely.
"Retatrutide treatment resulted in significant reduction of liver fat content and improvement in markers of liver health in patients with metabolic dysfunction-associated steatotic liver disease." — Sanyal et al. 2024, Nature Medicine
The metabolic benefits — hepatic fat reduction, improved lipids, better insulin sensitivity — persist into the taper, which is another reason to step down gradually rather than abruptly stop a tool that's actively improving your bloodwork.
Body Transformation Preview
Lean Mass Gain
0.0 lbs
0.0–0.0 lbs range
Fat Loss
20.7 lbs
15.6–25.9 lbs range
Fat Loss by Week
Risks & mistakes
Common (most users)#
The GI profile is the defining side-effect signature of retatrutide, and it tracks dose and titration speed more than anything else. Most of what follows is manageable if you respect the 4-week titration schedule.
- Nausea — by far the most common complaint, peaking in the first 1–2 weeks after each dose increase. Up to ~35% of users at higher doses in trials. Mitigation: smaller meals, avoid greasy/high-fat food on injection day, inject in the evening so you sleep through the peak, consider splitting the weekly dose into two half-doses (PK-justified by the ~6-day half-life). Ginger and ondansetron 4 mg PRN both work well. If nausea is still rough after 2 weeks at a dose, hold — don't titrate up.
- Constipation / diarrhea — GI motility gets scrambled. Mitigation: 30+ g fiber/day, 3+ L water, magnesium citrate 400 mg at night for constipation; loperamide PRN for the diarrhea swing.
- Decreased appetite — this is the mechanism, not a side effect, but it becomes a problem when it crushes protein intake. Mitigation: set a hard protein floor (1.0 g/lb LBM minimum, 1.2+ if cutting aggressively), eat it whether you want to or not. Protein shakes and Greek yogurt go down easier than solid meat when appetite is gone. If protein intake cannot be maintained at the current dose, the dose may be too high.
- Fatigue during titration — common in the first 2–4 weeks and after each step up. Usually reflects an abrupt caloric deficit more than a direct drug effect. Mitigation: don't cut training volume, do eat enough carbs on training days, electrolytes (sodium + potassium) help more than people expect.
- Injection site reactions — mild redness, itching, small welt. Mitigation: rotate between abdomen, thigh, upper arm; let the reconstituted solution warm to room temp before injecting; use a fresh 29–31G insulin pin each time.
- Mild resting heart rate increase — averaged +3–6 bpm in trials, class effect of GLP-1s. Mitigation: usually doesn't need intervention. If you're already on cycle and running elevated RHR, telmisartan 40–80 mg handles both BP and helps keep RHR in check.
Uncommon (dose-dependent or individual)#
These show up in the 6 mg+ range or in susceptible users. When they show up, the answer is usually "back down one dose step," not "tough it out."
- Persistent vomiting — beyond the first few days of a new dose. This is your signal that titration was too fast. Action: drop back to the previous tolerated dose for another 4 weeks before trying again.
- Mild fasting hyperglycemia in non-diabetics at high doses — the glucagon arm can bump FBG modestly in users who don't have a strong GLP-1/GIP counter-response. Check: HbA1c and fasting glucose at 12 weeks. If FBG trends >110, drop the dose.
- Lipid shifts — usually favorable (LDL/TG down with weight loss), but occasional users see LDL rise on the glucagon arm. Check: full lipid panel at 12 weeks.
- Mild liver enzyme movement — usually downward as hepatic fat drops, which is the point (Sanyal et al. 2024), but check at 12 weeks regardless.
"Retatrutide treatment resulted in significant reduction of liver fat content and improvement in markers of liver health in patients with metabolic dysfunction-associated steatotic liver disease." — Sanyal et al., Nature Medicine (2024)
- Gallbladder events — rapid weight loss at any dose increases gallstone risk. Warning signs: RUQ pain, especially after fatty meals, referred pain to the right shoulder blade.
- Lean mass loss — the #1 physique-user pitfall, not a pharmacologic side effect per se but a predictable consequence of aggressive weight loss without countermeasures. Without protection, 20–40% of total weight lost can be lean mass. Mitigation (non-negotiable): 1.0–1.2 g/lb LBM protein, heavy resistance training 3–4×/week, TRT-dose testosterone minimum if you're a male physique user running this as a cut.
Rare but serious#
Low incidence, but you need to know the warning signs.
- Pancreatitis — class signal across all incretin-based drugs. Warning signs: severe, persistent upper abdominal pain radiating to the back, often with vomiting that doesn't respond to the usual. Action: stop immediately, get lipase checked, ER if severe.
- Severe gastroparesis — extreme gastric emptying delay. Presents as early satiety, bloating, vomiting undigested food hours after eating. Action: stop, let gastric motility recover, do not restart without imaging workup.
- Severe hypoglycemia — rare in non-diabetics on retatrutide alone (glucose-dependent insulin secretion). Real risk if stacked with sulfonylureas or exogenous insulin. Action: do not stack with insulin without medical supervision.
- Acute kidney injury — almost always secondary to dehydration from vomiting/diarrhea, not a direct drug effect. Mitigation: aggressive hydration during GI flares.
Hard contraindications#
These lines do not get crossed. No "probably fine at low dose" — just don't.
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN-2 syndrome. Class boxed warning based on rodent C-cell tumor signal. Not worth the risk.
- History of pancreatitis. Any prior episode is a hard stop.
- Pregnancy or planned pregnancy within ~2 months of last dose. The ~6-day half-life means full washout takes ~30 days; give it 2 months before conception attempts. Not studied in pregnancy and actively causes weight loss — incompatible with fetal development.
- Type 1 diabetes. The glucagon arm makes glucose management unpredictable. Not studied, don't extrapolate.
- Active severe gastroparesis. Retatrutide will make it dramatically worse.
- Stacking with another GLP-1 or GLP-1/GIP agonist (semaglutide, tirzepatide, liraglutide). Additive GI toxicity, zero additional efficacy. Wash out ~2 weeks before switching.
Gender-specific considerations and PCT#
Retatrutide is non-hormonal — no HPTA suppression, no virilization risk, no aromatization, no 5-AR pathway interaction. Women run the same dose structure as men. Female physique users typically land at slightly lower effective doses (2–4 mg vs 4–6 mg for equivalent results) because of lower body mass, not because of sex-specific pharmacology.
Pregnancy is the only sex-specific hard stop. Discontinue at least 2 months before conception attempts, and do not use while breastfeeding.
No PCT required. Retatrutide does not suppress testosterone, LH, or FSH. If you're running it alongside a suppressive AAS cycle, run your normal PCT for the AAS — retatrutide itself doesn't enter that calculus. The only cessation concern is rebound weight gain: appetite returns, often stronger than baseline for a few weeks. Taper off by stepping back down the titration ladder over 4–8 weeks rather than stopping cold, and have a maintenance calorie and training plan ready before the last dose.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.05 | ×1.23 | ×1.08 | |
| synergistic | ×1.10 | ×1.08 | ×1.22 | |
| synergistic | ×1.05 | ×1.22 | ×1.00 | |
| synergistic | ×1.15 | ×1.20 | ×1.10 | |
| synergistic | ×1.08 | ×1.20 | ×1.15 | |
| synergistic | ×1.10 | ×1.18 | ×1.10 | |
| synergistic | ×1.13 | ×1.09 | ×1.07 |
Featured in stacks1 curated protocol include Retatrutide
FAQ — Retatrutide
Where to buy
Real Peptides
Affiliate link — we may earn a commission at no cost to you.
- Trinity-X™ (GLP-3RT)Buy Retatrutide
Research & citations
4 studies cited on this page.
Conclusion
Retatrutide is the new class leader for pharmacologic fat loss — combining triple-receptor appetite suppression and real thermogenic output, it outpaces everything in the current metabolic arsenal when run properly.
Key takeaways:
- Effective weekly dose: 1–4 mg for most physique-focused users, titrated up by 1 mg every 3–4 weeks; rarely is >6 mg needed outside extreme obesity
- Route: subcutaneous injection, typically once weekly, but split dosing (twice weekly) can help GI side effects
- Cycle length: 12–24 weeks per cut; taper off instead of stopping cold to minimize rebound
- Stack with TRT-dose testosterone to protect lean mass, and consider low-dose tadalafil or telmisartan to address mild BP or heart rate increases
- Appetite suppression and energy expenditure both drive fat loss — but set a non-negotiable daily protein minimum and keep training heavy to avoid muscle loss
- Do not stack with other GLP-1/GIP agonists; monitor for GI and thyroid-class effects
- Hard contraindications: personal/family medullary thyroid cancer, MEN-2, pancreatitis history, pregnancy
If you want industry-leading fat loss from a peptide, and you can manage the dosing and nutrition details, retatrutide is as high-leverage (and fast-acting) as the current research market gets.123